b16 cell line cl-0029 (Procell Inc)
Structured Review

B16 Cell Line Cl 0029, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b16 cell line cl-0029/product/Procell Inc
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "VSV-CHIKV activates antitumor immunity by inducing pyroptosis in a melanoma model"
Article Title: VSV-CHIKV activates antitumor immunity by inducing pyroptosis in a melanoma model
Journal: Discover Oncology
doi: 10.1007/s12672-025-02788-6
Figure Legend Snippet: Oncolytic VSV-CHIKV induces melanoma cell death (MOI = 1, 24 h). A Schematic showing the wild-type VSV and chimeric VSV-CHIKV genomes, in which the VSV glycoprotein G gene (blue) is replaced by the chikungunya glycoprotein sequence in the CHIKV structural polyprotein (green). B Images obtained by microscopy showing changes in VSV-CHIKV infection of B16 cells (scale bar: 20 μm). C LDH release from the culture supernatant of B16 cells infected with VSV-CHIKV (n = 3). *** P < 0.001 by t test. D Fluorescence microscopy observation of PI uptake in B16 cells (scale bars: 50 μm). *** P < 0.001 by t test. E The levels of IL-1β and IL-18 in the cell culture supernatant (n = 3). *** P < 0.001 by t test. F Western blot analysis of NLRP3, Caspase1, and Cleaved-caspase1 protein expression after the addition of VSV-CHIKV
Techniques Used: Sequencing, Microscopy, Infection, Fluorescence, Cell Culture, Western Blot, Expressing
Figure Legend Snippet: Oncolytic VSV-CHIKV causes pyroptosis in a melanoma cancer model. A Schematic illustration of the experimental design. B16 cell tumor-bearing C57BL/6 mice were intratumorally treated with VSV-CHIKV. B B16 tumors collected after VSV-CHIKV infection; images of the tumors, tumors weights (n = 6), body weight (n = 6), tumors growth curves are shown. ** P < 0.01 by t test. *** P < 0.001 by t test. C IL-1β and IL-18 levels in tumor tissues (n = 3). *** P < 0.001 by t test. D NLRP3, Caspase1, Cleaved-caspase1, GSDMD and GSDMD-N proteins in the mock group and the VSV-CHIKV group determined by Western blotting. E Immunohistochemical staining for the NLRP3, Caspase1, Cleaved-caspase1, GSDMD and GSDMD-N proteins in the mock group and the VSV-CHIKV group (scale bar: 100 μm). F HE staining of major organs (scale bar: 100 μm)
Techniques Used: Infection, Western Blot, Immunohistochemical staining, Staining
Figure Legend Snippet: Inhibition of GSDMD impairs VSV-CHIKV-induced melanoma tumor suppression. A Schematic illustration of the experimental design. B16 cell tumor-bearing C57BL/6 mice were intratumorally treated with VSV-CHIKV, VSV-CHIKV + Vehicle, or VSV-CHIKV + LDC7559. B B16 tumors from the VSV-CHIKV, VSV-CHIKV + Vehicle, and VSV-CHIKV + LDC7559 groups were collected after treatment; images of the tumors, tumors weights (n = 6), body weight (n = 6) and tumors growth curves are shown. *** P < 0.001 by One-way ANOVA. C The levels of IL-1β and IL-18 in tumor tissues (n = 3). *** P < 0.001 by One-way ANOVA. D Expression of the NLRP3, Caspase1, Cleaved-caspase1, GSDMD and GSDMD-N proteins in the VSV-CHIKV, VSV-CHIKV + Vehicle and VSV-CHIKV + LDC7559 groups determined by Western blotting. E Immunohistochemical staining for the NLRP3, Caspase1, Cleaved-caspase1, GSDMD and GSDMD-N proteins in the VSV-CHIKV, VSV-CHIKV + Vehicle and VSV-CHIKV + LDC7559 groups (scale bar: 100 μm). F HE staining of major organs (scale bar: 100 μm)
Techniques Used: Inhibition, Expressing, Western Blot, Immunohistochemical staining, Staining
Figure Legend Snippet: VSV-CHIKV-based virotherapy enhances the efficacy of immune checkpoint blockade. A Schematic illustration of the experimental design. B16 cell tumor-bearing C57BL/6 mice were intratumorally treated with VSV-CHIKV and intraperitoneally treated with aPD-1 (5 mg/kg). B Kaplan–Meier survival curves were generated (n = 10)
Techniques Used: Generated
Figure Legend Snippet: Melanoma cell pyroptosis triggered by oncolytic VSV-CHIKV is mediated by the NLRP3/Caspase-1/GSDMD axis (MOI = 1, 24 h). A Western blot analysis of GSDMD and GSDMD-N protein expression after the addition of VSV-CHIKV. B Expression of the GSDMD-N protein in the cytoplasm of cells after VSV-CHIKV infection of B16 cells. GSDMD-N, red; DAPI, blue (scale bar: 10 μm). *** P < 0.001 by t test. C Images obtained by microscopy showing changes in B16 cells after the addition of LDC7559 (scale bar: 20 μm). D LDH release from culture supernatants of B16 cells after the addition of LDC7559 (n = 3). *** P < 0.001 by One-way ANOVA. E Fluorescence microscopy of PI uptake in B16 cells after the addition of LDC7559 (scale bar: 50 μm). *** P < 0.001 by One-way ANOVA. F The levels of IL-1β and IL-18 in the cell culture supernatant after the addition of LDC7559 (n = 3). ** P < 0.01, *** P < 0.001 by One-way ANOVA. G Western blot analysis of NLRP3, Caspase1, Cleaved-caspase1, GSDMD and GSDMD-N protein expression after the addition of LDC7559. H Expression of GSDMD-N protein in the cytoplasm of cells after the addition of LDC7559 to B16 cells. GSDMD-N, red; DAPI, blue (scale bar: 10 μm). *** P < 0.001 by One-way ANOVA
Techniques Used: Western Blot, Expressing, Infection, Microscopy, Fluorescence, Cell Culture